TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A post hoc analysis of the WAHA randomized trial found that older adults assigned to eat walnuts daily had about 6% higher total IgG after two years than controls. The study did not show that walnuts improved immune protection or cardiovascular outcomes, and it found no significant effects on several other measured immune markers.
A post hoc analysis of the Walnuts and Healthy Aging (WAHA) trial found that older adults assigned to eat walnuts daily had about 6% higher total serum IgG after two years than participants assigned to avoid walnuts. Published in JACC Advances, the analysis reports a difference in an immune-system biomarker, but it does not establish that walnuts improve immunity or prevent cardiovascular disease.
The WAHA trial randomized 708 cognitively healthy adults aged 63 to 79 in the United States and Spain to a walnut-based diet or a control diet that excluded walnuts. Participants in the intervention group were asked to eat 30 to 60 grams of walnuts a day, equivalent to about 15% of daily energy intake, for two years. The original trial focused on cognitive function and retinal health; the new report is a later analysis of immune-related measures.
Researchers tested stored blood samples from 474 participants at the start and end of the two years: 240 in the walnut group and 234 in the control group. They measured total IgG and IgM, antibodies targeting MDA-modified LDL, and circulating MDA-LDL. The overall IgG difference was adjusted for baseline values and other factors, including age, sex, smoking, cholesterol, body mass index, and health conditions.
The result varied by study location. The analysis found 11% higher total IgG in the walnut group than controls among US participants, but no statistically significant intervention effect in Spain. It found no significant walnut-related differences in total IgM, MDA-LDL concentrations, or antibodies targeting MDA-LDL. Several markers, including total IgG and IgM, declined over time in both groups.
What the IgG Difference Can Tell Us
IgG is an antibody class involved in the body’s humoral immune response. A change in its concentration can be of scientific interest, but a higher total level does not by itself show that a person is better protected against infection or has lower inflammation. The analysis measured a blood biomarker, not illness rates, immune function in everyday life, or cardiovascular events.
The finding matters because it adds evidence about a possible relationship between a common food and immune markers in older adults. The researchers examined this in connection with atherosclerosis, a condition involving plaque buildup and inflammation in blood vessels. However, the study did not show that the IgG difference altered plaque formation or reduced heart attacks, strokes, or other clinical outcomes. Readers should not interpret the result as proof that walnuts treat or prevent disease.
The pattern also calls for caution: the effect was not statistically significant in Spain, and the other measured antibody and LDL-related markers did not show significant intervention effects. The results point to a question for further research, rather than a dietary prescription based on IgG alone.
Products Worth Considering
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
Garmin Venu® 3 Premium Fitness Smartwatch 45mm Black
As an affiliate, we earn on qualifying purchases.
How the WAHA Analysis Was Conducted
The WAHA trial enrolled participants from May 2012 to May 2014. People who already ate more than two servings of tree nuts each week were excluded, as were some people using specified oil or soy lecithin supplements. Participants attended follow-up visits every two months, where researchers monitored weight, tolerance, adherence, and medication use.
This report is a post hoc analysis: the original trial was not designed primarily to test these immune outcomes. The researchers used blood samples from a subset of participants and statistical models adjusted for several characteristics. Among Spanish participants, red blood cell alpha-linolenic acid levels rose by 426% in the walnut group and fell by 6% in controls, a measure the report used to support adherence to the assigned diets.
The authors also refer to earlier research associating higher IgG or certain antibodies against oxidized LDL with cardiovascular measures. Those findings provide background, not proof that the walnut-associated IgG difference in this analysis leads to a cardiovascular benefit.
“The clinical implications remain uncertain.”
— The study authors, as described in the report
What the Biomarker Does Not Show
The analysis does not explain why the IgG difference appeared in the combined sample but not in the Spain-only results, or whether the difference has any practical effect on health. It also cannot establish that the higher IgG caused a change in immune protection: the report describes an association between assigned diet and a measured concentration, not a demonstrated mechanism or clinical benefit.
Only 474 of the 708 trial participants were included in the biomarker analysis, and the immune measurements were not the original trial’s main outcomes. The source report does not provide evidence that the result applies to younger adults, people with significant health conditions, or people who already eat substantial amounts of nuts. Longer-term effects and any impact on cardiovascular events remain unestablished.
Further Trials Must Test Health Outcomes
The current report presents results from a two-year analysis; it does not announce a new trial or provide a timeline for follow-up research. The next evidence needed would include studies designed in advance to test immune outcomes, explain differences between locations, and determine whether biomarker changes correspond to meaningful health measures.
Until such evidence is available, the study supports only a narrow conclusion: in this group of older adults, assignment to a daily walnut diet was associated with higher total IgG overall, with differences by study center. It does not establish that eating walnuts boosts immunity or reduces cardiovascular risk.
Key Questions
What did the study find about walnuts and IgG?
In a post hoc analysis of the WAHA trial, participants assigned to eat 30 to 60 grams of walnuts daily had about 6% higher total serum IgG after two years than controls across the two study centers. The US subgroup showed an 11% difference; the Spain subgroup did not show a statistically significant effect.
Does higher IgG mean stronger immunity?
Not necessarily. IgG is an antibody and a marker of humoral immune status, but this study did not test whether the measured difference improved protection from infection or changed other health outcomes.
Did walnuts change the other immune markers?
The analysis found no significant intervention effect on total IgM, circulating MDA-LDL, or antibodies targeting MDA-LDL. Total IgG and IgM declined over the two years in both diet groups.
Did the study show that walnuts prevent heart disease?
No. The analysis did not measure or establish a reduction in heart attacks, strokes, or other cardiovascular events. It examined blood biomarkers related to immune activity and atherosclerosis.
Who took part in the trial?
The parent WAHA trial included 708 cognitively healthy adults aged 63 to 79 in the United States and Spain. Biomarker results were available for 474 participants, so the findings may not apply to every age group or health background.
Source: news-medical.net
